Endometrial cancer, a type of cancer that affects the lining of the uterus, is one of the most common gynecologic malignancies worldwide. According to the World Health Organization (WHO), endometrial cancer is the sixth most common cancer in women, with approximately 320,000 new cases and 76,000 deaths reported annually. In the United States alone, the American Cancer Society estimates that approximately 61,380 new cases of endometrial cancer will be diagnosed in 2022, resulting in approximately 10,920 deaths. Despite the alarming incidence and mortality rates, endometrial cancer remains a significant public health concern, warranting a comprehensive understanding of its crash rate, risk factors, and pathological anatomy.

Risk factors, effects, technology, diagnosis, treatments, obesity.

American Cancer Society: Cancer Facts and Figures 2024. American Cancer Society, 2024. Available online Exit Disclaimer. Last accessed January 17, 2024.

Ward KK, Shah NR, Saenz CC, et al.: Cardiovascular disease is the leading cause of death among endometrial cancer patients. Gynecol Oncol 126 (2): 176-9, 2012.

Beral V, Bull D, Reeves G, et al.: Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365 (9470): 1543-51, 2005 Apr 30-May 6.

Anderson GL, Limacher M, Assaf AR, et al.: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (14): 1701-12, 2004.

Furness S, Roberts H, Marjoribanks J, et al.: Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev (2): CD000402, 2009.

Grady D, Gebretsadik T, Kerlikowske K, et al.: Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85 (2): 304-13, 1995.